<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7535B4A7-ECE9-4106-8B06-3C7906532538"><gtr:id>7535B4A7-ECE9-4106-8B06-3C7906532538</gtr:id><gtr:name>Envigo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7535B4A7-ECE9-4106-8B06-3C7906532538"><gtr:id>7535B4A7-ECE9-4106-8B06-3C7906532538</gtr:id><gtr:name>Envigo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/04B6A2AB-0C99-425B-98F3-5F2CDFF2D434"><gtr:id>04B6A2AB-0C99-425B-98F3-5F2CDFF2D434</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Noble</gtr:surname><gtr:orcidId>0000-0002-3060-3772</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/39A367CA-12EE-4913-85A1-7C27976C496B"><gtr:id>39A367CA-12EE-4913-85A1-7C27976C496B</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Buchan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95DF1C05-09A0-412A-87F2-6D0A6175BFD7"><gtr:id>95DF1C05-09A0-412A-87F2-6D0A6175BFD7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0549AE03-83A7-456B-B9EC-6790271B75F3"><gtr:id>0549AE03-83A7-456B-B9EC-6790271B75F3</gtr:id><gtr:firstName>Chas</gtr:firstName><gtr:surname>Bountra</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CF74B8C4-3225-4D0E-B74A-C21D1CC10B5B"><gtr:id>CF74B8C4-3225-4D0E-B74A-C21D1CC10B5B</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Brouard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AE7C12E7-0A2F-4387-B254-0162D531A23E"><gtr:id>AE7C12E7-0A2F-4387-B254-0162D531A23E</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Samson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AB9A1DD7-6E64-4042-9440-5CA9F064300A"><gtr:id>AB9A1DD7-6E64-4042-9440-5CA9F064300A</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Geddes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65AB0A9D-E8A0-458C-92B9-E13CEDF1726D"><gtr:id>65AB0A9D-E8A0-458C-92B9-E13CEDF1726D</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Hobbs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A2BC6D31-BC0E-4ABE-B6E0-2D94708C3A1F"><gtr:id>A2BC6D31-BC0E-4ABE-B6E0-2D94708C3A1F</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Alistair</gtr:otherNames><gtr:surname>Robbins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/125B6E81-3FE3-470D-B4DA-705FCD322D92"><gtr:id>125B6E81-3FE3-470D-B4DA-705FCD322D92</gtr:id><gtr:firstName>Georg</gtr:firstName><gtr:otherNames>Andreas</gtr:otherNames><gtr:surname>Holl?nder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9D846A83-DFE6-4AF2-A9E7-BA990B0931EE"><gtr:id>9D846A83-DFE6-4AF2-A9E7-BA990B0931EE</gtr:id><gtr:firstName>N</gtr:firstName><gtr:surname>Emptage</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2C32BD53-810D-456C-8D78-33AF23232E95"><gtr:id>2C32BD53-810D-456C-8D78-33AF23232E95</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Kennedy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65CF431F-3B89-4644-9ECB-ABF60D41526A"><gtr:id>65CF431F-3B89-4644-9ECB-ABF60D41526A</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Bell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D7E9C1F0-D945-4C6E-A909-C32B3F6AAF99"><gtr:id>D7E9C1F0-D945-4C6E-A909-C32B3F6AAF99</gtr:id><gtr:firstName>Donal</gtr:firstName><gtr:otherNames>Donat</gtr:otherNames><gtr:surname>Bradley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5AF2C92C-4DF1-427B-BB41-2C82450D6B36"><gtr:id>5AF2C92C-4DF1-427B-BB41-2C82450D6B36</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Carr</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/80B6FB18-511C-4377-883B-4989FBE79A2D"><gtr:id>80B6FB18-511C-4377-883B-4989FBE79A2D</gtr:id><gtr:firstName>Freddie</gtr:firstName><gtr:surname>Hamdy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A902DB7E-5D05-49BC-BCD5-901CA428016D"><gtr:id>A902DB7E-5D05-49BC-BCD5-901CA428016D</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Ratcliffe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D16D4381-845C-40E0-9FAE-A4E66C00888B"><gtr:id>D16D4381-845C-40E0-9FAE-A4E66C00888B</gtr:id><gtr:firstName>Hugh</gtr:firstName><gtr:surname>Watkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/000EA2B7-E296-4D75-B9A5-8E35AAEEEF42"><gtr:id>000EA2B7-E296-4D75-B9A5-8E35AAEEEF42</gtr:id><gtr:firstName>Lionel</gtr:firstName><gtr:surname>Tarassenko</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/434630DA-F0E3-406B-B4DA-87FBDEF552FD"><gtr:id>434630DA-F0E3-406B-B4DA-87FBDEF552FD</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:surname>Channon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3A08924-3211-47F9-A709-DC28DAD85A96"><gtr:id>C3A08924-3211-47F9-A709-DC28DAD85A96</gtr:id><gtr:firstName>Rory</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1697E489-7385-4E68-84DC-C4D5761AC3E1"><gtr:id>1697E489-7385-4E68-84DC-C4D5761AC3E1</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Kennard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A536DD0C-05E7-4DCE-899C-25B41BFA1DBB"><gtr:id>A536DD0C-05E7-4DCE-899C-25B41BFA1DBB</gtr:id><gtr:firstName>Glyn</gtr:firstName><gtr:surname>Humphreys</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15029"><gtr:id>8E77EB43-5E21-44B8-B1C1-F8AF345B85E0</gtr:id><gtr:title>University of Oxford Confidence in Concept Scheme ? Round 4</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15029</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>850000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Department of Chemistry, University of Sheffield</gtr:description><gtr:id>159D461C-DEF2-4588-B9C9-1BD137B5DD72</gtr:id><gtr:impact>Multi-disciplinary (Chemistry) to add to Biological/Medical Science.</gtr:impact><gtr:outcomeId>58c8258d364f72.72635715-1</gtr:outcomeId><gtr:partnerContribution>Partners bring chemical synthesis expertise.</gtr:partnerContribution><gtr:piContribution>Research collaboration to develop new chemical class of radiosensitizer for drug delivery. Synthetic source of chemical(s) for MRC CiC award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Physical and Theoretical Chemistry Laboratory</gtr:department><gtr:description>Dept Of Physical Chemistry, University of Oxford</gtr:description><gtr:id>17905A80-43C8-4C2F-BC11-3AECADB2A997</gtr:id><gtr:impact>CIC Funding
UCSF funding
Patents pending</gtr:impact><gtr:outcomeId>58c15fbff36d43.91377134-1</gtr:outcomeId><gtr:partnerContribution>Partners bring expertise in microfluidics</gtr:partnerContribution><gtr:piContribution>Research collaboration to develop microfluidic diagnostic platforms. Awarded MRC CiC grant and UCSF award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Envigo</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Monoclonal antibody production against vaccine antigen</gtr:description><gtr:id>EE7ECAF5-0707-41A7-9E24-C019004C6959</gtr:id><gtr:impact>Collaboration in place; results pending.</gtr:impact><gtr:outcomeId>58ca71b8812d22.31972918-1</gtr:outcomeId><gtr:partnerContribution>Antibodies specific to our novel vaccine antigen do not exist leading to a reliance on non-specific fusion tags. In collaboration with us, our partner will supply this valuable new resource which will enable accurate data interpretation of the effects of new vaccine candidates.</gtr:partnerContribution><gtr:piContribution>We have secured funding for this collaboration. We developed and supplied the protein vaccine antigen and will test functionality of mAb generated by different clones selected by our collaborator.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assay development to facilitate vaccine progression for Shingles</gtr:description><gtr:id>7A4E3DF7-32BF-451A-9ED2-0FE8B29C4B43</gtr:id><gtr:impact>Collaboration in place; results pending.</gtr:impact><gtr:outcomeId>58c95178d695c8.07542186-1</gtr:outcomeId><gtr:partnerContribution>To facilitate the progress to market of new VZV-specific vaccines, we propose to develop a standardized peptide-based ELISPOT assay, which will be specific, reproducible, reliable and easily transferrable. Works carried out in Prof. Fletcher's laboratory will aid in the assessment of the ease to which the assay can be transferred.</gtr:partnerContribution><gtr:piContribution>Transfer of assay and SOP to other laboratories. We will collaborate with Prof Helen Fletcher, based at the London School of Hygiene &amp;amp; Tropical Medicine, to transfer the newly developed assay and compare the outputs for reproducibility, accuracy and robustness.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>EIT Health Summer School Rare Cancer</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>865C61C6-FADA-4ECF-B268-74796588E61E</gtr:id><gtr:impact>EIT health summer in Rare cancer at two centres Budapest and Oxford.
Innovation by design and educational summer school</gtr:impact><gtr:outcomeId>58c3f30f1c1745.46886747</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Norway: Oslo and Bergen lectures&quot; Challenges of Rare Cancers&quot; and 'Evolution of an IGF2-TRAP'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D3821F9A-82D3-42D7-A3A9-2EA583008502</gtr:id><gtr:impact>Two lectures given in Bergen and video linked to Oslo Radium Hospital and Institute of Cancer Research</gtr:impact><gtr:outcomeId>58c3f3a27c7d20.21288236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Advisory Board for Hungarian Academy of Sciences: Hungary Institute of Molecular Medicine</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CE66F1E6-BC9C-4DE8-8D93-30C66DA6FB32</gtr:id><gtr:impact>Presentation on Oxford and Thames Valley Molecular Medicine Developments. Workshop and closed advisory board on the Development of a Hungarian Institute of Molecular Medicine.</gtr:impact><gtr:outcomeId>58c3f43a608356.67555100</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EIT health Rotterdam Meeting: Rare Cancer Project presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DF2556BF-36B7-42E9-8B70-C294D57EC8B7</gtr:id><gtr:impact>Presenation of an EIT health project on Rare Cancer to the kick-off meeting in Rotterdam</gtr:impact><gtr:outcomeId>58c3f517716880.76633930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cell and Gene Therapy Congress</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6F7E4C18-21AF-4F02-8A72-1BD53F941D52</gtr:id><gtr:impact>Plenary speaker at an international congress.</gtr:impact><gtr:outcomeId>58c47fcece7829.41034738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GlaxoSmithKline</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AD31393F-421B-4814-B881-C121B565C025</gtr:id><gtr:impact>An invitation to contribute to a seminar series.</gtr:impact><gtr:outcomeId>58c4807647d5c9.67486994</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>9700</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Oxford Radcliffe Hospitals Charitable Fund</gtr:fundingOrg><gtr:fundingRef>OHSRC 1231</gtr:fundingRef><gtr:id>FEC8DBF6-0045-4C5E-A10B-7281F8CA5ED4</gtr:id><gtr:outcomeId>58c46af2bcf535.22138804</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research project grant</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>A1372</gtr:fundingRef><gtr:id>94FDB465-B0A3-4604-9998-98641B6053A7</gtr:id><gtr:outcomeId>58c46859f313d9.09452501</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>Hungary, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EIT Health Rare Cancer Project (KIC) Stage 1</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>European Institute of Innovation and Technology (EIT)</gtr:fundingOrg><gtr:id>31BCD8C3-EDC1-45BB-9AD7-470E20921785</gtr:id><gtr:outcomeId>58c3f0bab57357.94564042</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33835</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept Round 4</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1220F21F-DD6B-4574-BBC7-F08C7ED40C43</gtr:id><gtr:outcomeId>58c68480bd96b1.18197693</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CiC Award Oxford</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>52CE5B76-E5DC-4519-8EB6-B05F59B0742C</gtr:id><gtr:outcomeId>58c3f1ac8c9f32.19479845</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Cancer Research UK (CRUK) Oxford Centre</gtr:department><gtr:description>Development Fund Grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>CRUKDF 0716-PF</gtr:fundingRef><gtr:id>4EBBB7B8-22F4-4FB9-9A64-B44175FCCD6F</gtr:id><gtr:outcomeId>58c469dbceddb9.61271525</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK Oxford Centre Development Fund</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>67549231-41FF-4455-ADEB-B21A6FED8A7C</gtr:id><gtr:outcomeId>56cef54ea227c8.49015199</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66497</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCSF</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Oxford Innovation Ltd</gtr:fundingOrg><gtr:id>2108BEA6-5D36-4341-946F-F464A3491168</gtr:id><gtr:outcomeId>58c1635a4f6e36.40535447</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>390000</gtr:amountPounds><gtr:country>Hungary, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EIT Health PhD/DPhil Doctoral Transition Fellowships</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Institute of Innovation and Technology (EIT)</gtr:fundingOrg><gtr:id>38EE8B6F-F497-41E3-ADB1-86DB4234852E</gtr:id><gtr:outcomeId>58c3f13c95ab29.55727618</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Appointed to the Scientific Advisory Board of Universal Cells</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8035A128-BC0D-479A-8966-C112DD0AC76B</gtr:id><gtr:outcomeId>58c4815ab74034.46466373</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>iotaSciences Ltd</gtr:companyName><gtr:description>This company is commercializing a novel way of performing microfluidics</gtr:description><gtr:id>B5B3CED8-27C2-474B-8AED-E874589055A0</gtr:id><gtr:impact>This company is commercializing a novel way of performing microfluidics</gtr:impact><gtr:outcomeId>5894620441c052.95609876</gtr:outcomeId><gtr:url>http://iotaSciences.com</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>4659DEDC-72F2-4404-9C5E-97ECC4C5B7EF</gtr:id><gtr:title>Microfluidics with fluid walls.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bc77b1fac98c4e8c67ba129659d32d3"><gtr:id>0bc77b1fac98c4e8c67ba129659d32d3</gtr:id><gtr:otherNames>Walsh EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a35f97a32b4e3.50176455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A0C8377-D225-4F61-819B-0FCA9EEEC0C3</gtr:id><gtr:title>Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0101cf0b740c6a8fb18490511c31492a"><gtr:id>0101cf0b740c6a8fb18490511c31492a</gtr:id><gtr:otherNames>Frago S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58c3ee8bae5909.65785485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8E76A88-D81B-4639-9830-4CB31FA9A9E5</gtr:id><gtr:title>Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d62528515323b140c0b7f1efac5703d3"><gtr:id>d62528515323b140c0b7f1efac5703d3</gtr:id><gtr:otherNames>Jurynczyk M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>5aa66e8fc03834.25139954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B637E12-DCB8-423A-BB2A-FD0BDE56616D</gtr:id><gtr:title>Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141Subset.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cee7452eb96c6cf00e1815629a21e81"><gtr:id>5cee7452eb96c6cf00e1815629a21e81</gtr:id><gtr:otherNames>Sachamitr P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a6f2fc3d8d481.43367363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82E7D587-70A9-4CDE-959E-F968031A5061</gtr:id><gtr:title>Harnessing the properties of dendritic cells in the pursuit of immunological tolerance.</gtr:title><gtr:parentPublicationTitle>Biomedical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1688e1c253144f0fa3ab4bd64e498f5"><gtr:id>c1688e1c253144f0fa3ab4bd64e498f5</gtr:id><gtr:otherNames>Horton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2319-4170</gtr:issn><gtr:outcomeId>5aa7c1c7dadbd4.93679776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>366D4502-C67A-4769-9AC5-638B6BC8AD65</gtr:id><gtr:title>Potential for non-invasive assessment of lung inhomogeneity using highly precise, highly time-resolved, measurements of gas exchange.</gtr:title><gtr:parentPublicationTitle>Journal of applied physiology (Bethesda, Md. : 1985)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d39b822670434eb240583ed5ae713c75"><gtr:id>d39b822670434eb240583ed5ae713c75</gtr:id><gtr:otherNames>Mountain JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0161-7567</gtr:issn><gtr:outcomeId>5a6f2ffe146719.74114054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E941AD6-4388-4753-B3C7-138D28D45068</gtr:id><gtr:title>Biocompatibility of fluids for multiphase drops-in-drops microfluidics.</gtr:title><gtr:parentPublicationTitle>Biomedical microdevices</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcb9d009bac791e57d63e2273be3782b"><gtr:id>bcb9d009bac791e57d63e2273be3782b</gtr:id><gtr:otherNames>Prastowo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2176</gtr:issn><gtr:outcomeId>589462ceeb3752.80763551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>687CDD7C-445D-4BED-B8E6-EFC37269C602</gtr:id><gtr:title>A three-in-one-bullet for oesophageal cancer: replication fork collapse, spindle attachment failure and enhanced radiosensitivity generated by a ruthenium(
 
 ) metallo-intercalator</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9118d4809385694731fda7074c264445"><gtr:id>9118d4809385694731fda7074c264445</gtr:id><gtr:otherNames>Gill M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa7a0543136f4.54928066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E19BABE-9C34-49B1-8715-B3D6451B4E04</gtr:id><gtr:title>Challenges in dengue research: A computational perspective</gtr:title><gtr:parentPublicationTitle>Evolutionary Applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/768508077c69c7dc7b83142d699faaba"><gtr:id>768508077c69c7dc7b83142d699faaba</gtr:id><gtr:otherNames>Louren?o J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a6f2fdf9ae897.34856515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EE84981-8B39-4230-BA59-0233803D26BF</gtr:id><gtr:title>BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a58c1ee0200a1.44112394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80509E2B-AA54-42BC-9425-13AF67D2BBA5</gtr:id><gtr:title>Targeted radionuclide therapy in combined-modality regimens.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f319184989b26fcd3027cd7e313793"><gtr:id>99f319184989b26fcd3027cd7e313793</gtr:id><gtr:otherNames>Gill MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5aa79f2c7fa010.98360648</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15029</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>